Ignatius Ou SH, Solomon BJ, Besse B, Bearz A, et al. Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study. J Thorac Oncol 2024 Nov 22:S1556-0864(24)02484.
PMID: 39581380